ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...3940414243444546474849...129130»
  • ||||||||||  ivermectin oral / Generic mfg.
    Preclinical, Journal:  Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model. (Pubmed Central) -  Mar 27, 2022   
    This study contributes to the growing body of evidence that ivermectin does not result in a beneficial effect in the treatment of COVID-19. These findings are important given the increasing, dangerous off-label use of ivermectin for the treatment of COVID-19.
  • ||||||||||  hydroxychloroquine / Generic mfg., ivermectin oral / Generic mfg.
    Observational data, Journal:  Prescription Patterns of Drugs Given to Hospitalized COVID-19 Patients: A Cross-Sectional Study in Colombia. (Pubmed Central) -  Mar 26, 2022   
    Corticosteroids, anticoagulants, colchicine, azithromycin, ivermectin, and hydroxychloroquine were prescribed more frequently in men, and their overall use increased with age...The majority of patients were managed with medications included in the management guidelines. There were differences between sexes, age groups, and geographical regions.
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal:  Ivermectin and the Integrity of Healthcare Evidence During COVID-19. (Pubmed Central) -  Mar 25, 2022   
    Exemplar tools that develop critical appraisal skills will be noted, with reviews of ivermectin's efficacy explored as examples. As stakeholders in healthcare evidence are increasingly able to identify well-conducted and ethical research they will simultaneously be able to spot and reject fraudulent reports and prevent them from influencing healthcare decisions.
  • ||||||||||  hydroxychloroquine / Generic mfg., ivermectin oral / Generic mfg.
    Clinical, Journal:  Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial. (Pubmed Central) -  Mar 23, 2022   
    No difference in hospitalization duration was found between the treatment groups (Group1: 7 vs. Group 2: 6 vs. Group 3: 5, p = 0.43) nor in respiratory deterioration or death (Group 1: 18% vs. Group 2: 22.2% vs. Group 3: 24.3%, p = 0.83). In non-critical hospitalized patients with COVID-19 pneumonia, neither ivermectin nor hydroxychloroquine decreases the number of in-hospital days, respiratory deterioration, or deaths.
  • ||||||||||  dapsone / Generic mfg., ivermectin oral / Generic mfg.
    BLUE DESPITE O2: A RARE CASE OF METHEMOGLOBINEMIA ([VIRTUAL]) -  Mar 23, 2022 - Abstract #SCCM2022SCCM_2125;    
    The most common inciting factor is an exposure to oxidizing agents, such as various antibiotics (sulfonamides, trimethoprim, and dapsone), local anesthetics, nitrites, and aniline dyes...Interestingly, this patient developed this condition after being treated for COVID 19 with vitamin infusions. This case highlights the importance of careful history taking, as certain medications can have unknown and fatal side effects.
  • ||||||||||  ivermectin oral / Generic mfg.
    Management of Common Scabies and Post-Scabetic Itch in Adults: Lessons Learned from a Single-Center Retrospective Cohort Study (Poster Presentation Center 2) -  Mar 21, 2022 - Abstract #AAD2022AAD_2337;    
    Therefore, the proposed drugs might play a vital role for the treatment against different variants of SARS-CoV-2 infections. These findings support use of combined topical permethrin plus oral ivermectin therapy in treating common scabies, suggest post-scabetic itch can persist for longer than previously reported, and reveal a potential relationship between older age and post-scabetic itch.